News

QuatRx has reported the positive top-line efficacy results from the first of two patient cohorts in its second pivotal phase 3 trial of the investigational compound, Ophena (ospemifene

Cobble is director of Canyons Medical Center in Sandy, Utah. Cobble is a primary care physician, board-certified lipidologist and certified hypertension specialist. Cobble succeeds James Ehrlich, M.D., who

Covance has reported GAAP earnings for its second quarter ended June 30, 2009 of $0.67 per diluted share, inclusive of a $0.01 per share gain related to the

A new bill was introduced in the US legislature that proposes to overhaul the system for providing global development aid, reports Boston Globe. The bill, introduced on Tuesday,

Raptor and TorreyPines have entered into a merger agreement. As per the deal, the merged company will be named – Raptor and will be headquartered in California. Under

The Medicines Company has announced its financial results for the second quarter of 2009, where net revenue increased by 20% to $104.2 million from $86.7 million for the

Promius has launched Promiseb Topical Cream, a non-steroidal, prescription only, cream for the treatment of seborrheic dermatitis, that has demonstrated both anti-inflammatory and antifungal properties. Jeffrey Wasserstein, president

Watson has signed a licensing agreement with GeneraMedix for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection). The

Danisco’s HOWARU Protect probiotic formulation seems to provide a safe and effective means to enhance the body’s natural defense, and has been clinically shown to reduce the incidence